Insider Trading July 2, 2026 08:40 PM

Insider Accumulation at Jewett-Cameron: AJB Funds and Bradleys Purchase $25,871 in JCTC Shares

Ten percent owners AJB Investment Fund II, AJB Capital, and the Bradleys acquired 11,009 shares on July 1, 2026, as the company approaches earnings and shows undervaluation signals.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
JCTC

Several major stakeholders in Jewett-Cameron Trading Co Ltd (NASDAQ:JCTC), including AJB Investment Fund II, LP, AJB Capital, LLC, Adam James Bradley, and Melinda Hodges Bradley, have collectively purchased $25,871 worth of company stock. The acquisition of 11,009 shares occurred on July 1, 2026, at a price of $2.35 per share. This strategic buying activity has coincided with a recent 16% increase in the stock price over the past week, bringing the current valuation to $2.56 per share. According to InvestingPro analysis, Jewett-Cameron Trading Co Ltd is currently trading below its fair value, positioning it among the most undervalued opportunities in the market. The company is scheduled to report its earnings on July 20, 2026, providing a critical window for investors to assess the impact of recent financial results.

Insider Accumulation at Jewett-Cameron: AJB Funds and Bradleys Purchase $25,871 in JCTC Shares
JCTC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ten percent owners AJB Investment Fund II, LP, AJB Capital, LLC, and the Bradleys purchased 11,009 shares of JCTC at $2.35 per share on July 1, 2026.
  • The stock has risen 16% since the purchase date, reaching $2.56, with analysis indicating the company is undervalued below its fair value.
  • Jewett-Cameron Trading Co Ltd reported an 11% revenue increase to $9.1 million in Q2 FY2026 but posted a net loss of $0.6 million, contrasting with prior year net income.

Recent insider activity at Jewett-Cameron Trading Co Ltd (NASDAQ:JCTC) highlights a concerted buying effort by significant stakeholders in the company. Ten percent owners, specifically AJB Investment Fund II, LP, AJB Capital, LLC, Adam James Bradley, and Melinda Hodges Bradley, executed transactions totaling $25,871 on July 1, 2026. The acquisition involved the purchase of 11,009 shares of JCTC stock, each bought at a price of $2.35. This influx of capital from major insiders arrives as the stock demonstrates a 16% return over the past week, climbing from the purchase price to $2.56, according to InvestingPro analysis.

The structure of these purchases reveals specific allocation strategies across individual retirement accounts. Melinda Bradley indirectly acquired 5,000 shares, which are held within her individual retirement account. Concurrently, Adam Bradley secured 6,009 shares, also held in his individual retirement account. Both transactions were executed at the uniform price of $2.35 per share. Following these specific transactions, the reporting persons collectively hold an aggregate beneficial ownership of 382,016 shares of Jewett-Cameron Trading Co Ltd. This aggregate total comprises 300,186 shares held by AJB Investment Fund II, LP; 26,709 shares in Adam J. Bradley’s individual retirement account; 42,709 shares in Melinda Bradley’s individual retirement account; and 12,585 shares held in accounts owned by the adult children of Adam J. Bradley and Melinda Bradley, over which Adam J. Bradley exercises investment discretion.

Adam J. Bradley may be deemed to beneficially own all 382,016 shares reported. This encompasses his direct ownership, control of AJB Capital, and investment discretion over certain accounts. Melinda Bradley may be deemed to beneficially own 342,722 shares, comprising 300,186 shares held by AJB Investment Fund II, LP, where she shares voting and dispositive power as a managing member of AJB Capital, and 42,536 shares held in her individual retirement account. She does not exercise investment discretion over the 12,585 shares held in accounts owned by the adult children and therefore is not deemed to beneficially own such securities. Each reporting person disclaims beneficial ownership of all securities reported herein except to the extent of such person’s pecuniary interest therein.

The timing of these purchases is notable as Jewett-Cameron Trading Co Ltd approaches its earnings release on July 20, 2026. The company recently reported an 11% increase in revenue for the second quarter of fiscal year 2026, reaching $9.1 million compared to $8.2 million in the same period last year. Despite this revenue growth, the company faced a net loss of $0.6 million, or $0.16 per share, contrasting with a net income of $0.5 million, or $0.15 per share, in the second quarter of fiscal year 2025. No stock price movement was noted following the earnings release.

These developments provide a mixed picture for investors, with revenue growth on one hand and a net loss on the other. There were no updates regarding mergers or acquisitions. Additionally, no analyst upgrades or downgrades have been reported for Jewett-Cameron Trading Company. Investors might find these recent financial results significant as they assess the company’s performance. The company, with a market cap of $8.85 million, is scheduled to report earnings on July 20, 2026. Investors seeking deeper analysis can access JCTC’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro, which transforms complex financial data into clear, actionable intelligence.

Risks

  • Jewett-Cameron Trading Co Ltd reported a net loss of $0.6 million in Q2 FY2026, contrasting with prior year net income, highlighting profitability challenges in the small-cap market.
  • The company's $8.85 million market cap indicates limited liquidity and potential volatility, impacting risk assessment for investors in the financial services sector.
  • No analyst upgrades or downgrades have been reported, and no stock price movement was noted following earnings, suggesting limited market catalysts or clarity for the stock.

More from Insider Trading

Spyre Therapeutics CFO Executes Pre-Arranged Share Sales Amid Clinical Momentum Jul 2, 2026 Lightspeed Affiliates Divest $260K in Navan Shares Amid Post-IPO Restructuring Jul 2, 2026 Lightspeed Management Exits Navan Position; Company Pursues Strategic Acquisitions and AI Integrations Jul 2, 2026 Spyre Therapeutics CMO Sheldon Sloan Liquidates Holdings Following $730K Sale Jul 2, 2026 Spyre Therapeutics CEO Cameron Turtle Sells $1.32M in Shares Amid Pipeline Progress Jul 2, 2026